𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Risk of venous thromboembolism in patients receiving adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide for early breast cancer

✍ Scribed by Julia HOY; Teresa NEEMAN; Robin STUART-HARRIS; Alison DAVIS


Book ID
111318745
Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
107 KB
Volume
5
Category
Article
ISSN
1743-7555

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Phase I trial of adjuvant chemotherapy w
✍ Stephen E. Jones; Robert G. Mennel; George N. Peters; Mary Alice Westrick; Barry πŸ“‚ Article πŸ“… 1988 πŸ› Springer US 🌐 English βš– 263 KB

Epirubicin is a new anthracycline with a potentially more favorable toxicity profile than the parent compound, doxorubicin. Accordingly, the feasibility and toxicity of 6 courses of adjuvant chemotherapy with cyclophosphamide (C), epirubicin (E), and 5-fluorouracil (F) were assessed in 10 patients w